Contraception Clinical Trial
Official title:
Intervention to End Recurrent Unscheduled Bleeding Trial: A Randomized-controlled Trial of Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users
The subdermal etonogestrel (ENG) implant, a long-acting reversible contraceptive (LARC)
method, is among the most effective forms of reversible contraception and thus, an important
tool in the quest to reduce unintended pregnancy. However, despite overall increases in LARC
use in the United States from 1.5% in 2002 to 7.2% in 2011, and 11.6% most recently in 2015,
implant use continues to make up a small proportion of LARC use. While evidence to explain
this low uptake of implants is lacking, one potential reason is patient and provider concerns
about unpredictable bleeding.
As a result of this, many studies have been performed in attempts to discover therapies for
unscheduled bleeding in progestin-only contraceptive users. Some of these studies include
those investigating selective progesterone receptor modulators, such as mifepristone and
ulipristal acetate (UPA), which did find some benefit. Although a previous study showed mixed
benefit, the investigators feel that this medication has demonstrated both biologic
plausibility as well as clinically important outcomes. This previous study may not be
entirely translatable to the proposed research as therapies were used for different
indications (prophylaxis vs. treatment) and different progestins and delivery systems were
studied. Therefore, the investigators believe UPA should not be discounted as a potential
therapy. UPA may provide an additional safe and effective option for treatment of irregular
bleeding with implants in women. In addition, UPA is currently available in outpatient
pharmacies in the U.S. as a single 30mg oral tablet.
The investigators propose to investigate UPA for the treatment of unscheduled and troublesome
bleeding in ENG implant users.
The subdermal etonogestrel (ENG) implant, a long-acting reversible contraceptive (LARC)
method, is among the most effective forms of reversible contraception and thus, an important
tool in the quest to reduce unintended pregnancy. Despite this, ENG implant users make up a
small percent of overall women that use LARC in the United States. Previous studies have
demonstrated that among women dissatisfied with their implant, the majority cite
unpredictable and irregular bleeding as a primary reason. Dissatisfaction with a
contraceptive method can lead to discontinuation, which can put a woman at risk for unplanned
pregnancy. Although irregular bleeding is a common side effect of all progestin-only
contraceptives, there are significant gaps in our knowledge regarding the etiology of and
effective therapies for unscheduled bleeding. While several mechanisms have been proposed and
therapies have been studied, lack of convincing scientific evidence, in addition to possible
contraindications to these therapies, demonstrates the need to investigate additional
effective interventions.
Studies evaluating interventions for abnormal uterine bleeding resulting from uterine
leiomyoma provide insight into potential therapies for progestin-mediated bleeding. In prior
studies, ulipristal acetate (UPA) has been shown to reduce bleeding symptoms associated with
uterine leiomyoma, including decreasing or stopping excessive bleeding. Progestin-associated
irregular bleeding has been proposed to be secondary to a disruption in endometrial
angiogenesis, therefore creating a fragile venous network. UPA may displace local progestin
to counteract this effect. Thus, this medication has demonstrated both biologic plausibility
as well as clinically important benefits. UPA may provide an additional safe and effective
option for treatment of irregular bleeding in implant users. As women are often dissatisfied
with irregular bleeding with the implant as noted above, improving bleeding profiles could
potentially improve uptake and continuation of the device.
The investigators will perform a double blinded, randomized, placebo-controlled trial. Women
will be randomized to receive either 15mg of UPA daily for 7 days or placebo for the same
duration. The investigators hypothesize that UPA will decrease bleeding and spotting days in
users of the ENG implant with unscheduled bleeding when compared to placebo as assessed by
daily bleeding diaries.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |